Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Oncology
|
| gptkbp:affects |
bile ducts
|
| gptkbp:clinical_trial |
gptkb:immunotherapy
ongoing research targeted therapy |
| gptkbp:condition |
gptkb:virus
gptkb:hepatitis_C cirrhosis |
| gptkbp:death |
depends on stage
5-year survival rate low |
| gptkbp:diagnosis |
biopsy
imaging tests poor prognosis |
| gptkbp:diseases |
gptkb:Oncology
bile duct origin |
| gptkbp:epidemiology |
more common in men
more common in Asia |
| gptkbp:genetic_studies |
gptkb:Genetics
gptkb:TP53_mutation IDH1 mutation |
| gptkbp:healthcare |
gptkb:MRI
CT scan ultrasound |
| https://www.w3.org/2000/01/rdf-schema#label |
cholangiocarcinoma
|
| gptkbp:is_tested_for |
gptkb:AFP
CEA CA 19-9 |
| gptkbp:number_of_stages |
stage I
stage IV stage II stage III |
| gptkbp:patient_population |
older adults
rare in children |
| gptkbp:research_focus |
genetic studies
early detection new therapies |
| gptkbp:risk_factor |
liver fluke infection
primary sclerosing cholangitis |
| gptkbp:symptoms |
weight loss
abdominal pain jaundice |
| gptkbp:treatment |
gptkb:surgery
palliative care liver transplant radiation therapy chemotherapy surgical complications endoscopic procedures monitoring required late diagnosis recurrence risk |
| gptkbp:type |
extrahepatic cholangiocarcinoma
intrahepatic cholangiocarcinoma perihilar cholangiocarcinoma |
| gptkbp:bfsParent |
gptkb:Hillman_Cancer_Center_at_UPMC_Magee-Womens_Hospital
gptkb:Pemazyre gptkb:bile_duct_cancer |
| gptkbp:bfsLayer |
7
|